Journal Article Research Support, Non-U.S. Gov't Epublish 21 citations
PubMed: 35784553 DOI: 10.3389/fendo.2022.907984
Empagliflozin Attenuates Obesity-Related Kidney Dysfunction and NLRP3 Inflammasome Activity Through the HO-1-Adiponectin Axis.
Front Endocrinol (Lausanne) 13:907984
Authors: Tongtong Ye, Jingwen Zhang, Di Wu, Junfeng Shi, Zengguang Kuang, Yuting Ma, Qian Xu, Bing Chen, Chengxia Kan, Xiaodong Sun, Fang Han
Affiliations
- Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China. Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang, China.
- Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China. Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang, China. Department of Pathology, Affiliated Hospital of Weifang Medical University, Weifang, China.
- Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China.
- Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang, China.
Abstract
Empagliflozin (EMPA) is a novel sodium-glucose cotransporter 2 inhibitor (SGLT2i) that produces protective cardiovascular-renal outcomes in patients with diabetes. However, the effects of EMPA on obesity-related kidney disease have not been determined. The heme oxygenase-1 (HO-1)-adiponectin axis is an essential antioxidant system with anti-apoptotic and anti-inflammatory properties. This study explored whether EMPA improves obesity-related kidney disease through regulation of the renal HO-1-mediated adiponectin axis. C57BL/6J mice were assigned to control, high-fat diet (HFD) groups, and EMPA (10 mg/kg) groups. HFD mice showed metabolic abnormality and renal injury, including increased urinary albumin excretion, morphologic changes, and lipid accumulation. EMPA treatment improved metabolic disorders and attenuated lipotoxicity-induced renal injury. Furthermore, EMPA treatment ameliorated renal NLRP3 inflammasome activity and upregulated the HO-1-adiponectin axis. Our findings indicate that EMPA improves obesity-related kidney disease through reduction of NLRP3 inflammasome activity and upregulation of the HO-1-adiponectin axis, suggesting a novel mechanism for SGLT2i-mediated renal protection in obesity.
MeSH
Kidney Diseases, Adiponectin, Inflammasomes, Kidney, Obesity, Therapeutics, Endocrine System Diseases
Cited by
- Mechanistic and Molecular Insights into Empagliflozin's Role in Ferroptosis and Inflammation Trajectories in Acetaminophen-Induced Hepatotoxicity. Pharmaceuticals (Basel), 2025
- Integrated multi-omics analyses reveal effects of empagliflozin on intestinal homeostasis in high-fat-diet mice. iScience, 2023
- Signaling Pathways of Podocyte Injury in Diabetic Kidney Disease and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors. Cells, 2022
- Sodium-Glucose Cotransporter-2 Inhibitor Improves Renal Injury by Regulating the Redox Profile, Inflammatory Parameters, and Pyroptosis in an Experimental Model of Diabetic Kidney Disease. ACS Pharmacol Transl Sci, 2025
- Oxidative Stress Management in Cardiorenal Diseases: Focus on Novel Antidiabetic Agents, Finerenone, and Melatonin. Life (Basel), 2022
- SGLT-2 Inhibitors and the Inflammasome: What's Next in the 21st Century? Nutrients, 2023